{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-148822","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.700901+00:00","generated_at":"2026-06-25T18:36:52.888384+00:00","sec_items":["1.01","2.02","3.02","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cortexyme to merge with Novosteo; to issue ~6M shares, appoints Novosteo CEO as CEO","bullets":["Enters definitive agreement to acquire Novosteo via reverse merger; expects to issue ~6M shares in transaction.","Post-merger pro forma cash, cash equivalents and investments of ~$120M as of March 31, 2022.","Dirk Thye, MD (Novosteo CEO) to become Cortexyme CEO; Chris Lowe steps down as interim CEO but remains CFO/COO.","Philip Low, PhD appointed to Cortexyme board; independent board approves 4,000,000-share inducement plan for new hires.","Closing expected within 30 days, subject to Novosteo stockholder approval and other customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-148822","json":"https://secwatch.observer/filing/0001193125-22-148822.json","markdown":"https://secwatch.observer/filing/0001193125-22-148822.md","text":"https://secwatch.observer/filing/0001193125-22-148822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522148822/0001193125-22-148822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522148822/d316217d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:36:52.888384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8eae59b7c9","claim":"Dirk Thye was appointed as Chief Executive Officer at Quince Therapeutics, Inc..","evidence_excerpt":"the appointment of Dirk Thye, M.D. as the Chief Executive Officer of the Company and as principal executive officer and a Class II director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522148822/0001193125-22-148822-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}